Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
NCT ID: NCT04144816
Last Updated: 2019-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5000 participants
OBSERVATIONAL
2019-10-31
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Regarding the introduction of a new RSV vaccine and RSV-specific neutralizing antibodies, these data are of prime importance to guide future vaccine policies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France
NCT06881953
Impact of the Covid-19 on Respiratory Syncytial Virus (RSV) Epidemic
NCT04944160
Severity of RSV Infections in Twins
NCT05070975
Disease Burden of RSV
NCT05506670
Impact of the Covid-19 on RSV
NCT05348616
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To determine the main predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
Study design:
Prospective epidemiological, observational, one-center cohort study with sample collection.
Study population:
Birth cohort of infants born in Lyon before and during the RSV circulation period (October to march) with a follow-up until one year old (from birth until the age of 1 year maximum):
* Estimate Birth cohort (n=5,000).
* Estimate number of RSVH case (n=110).
* Estimate number of Blood cordon associated with a RSVH (Respiratory Syncytial Virus Human) case (n=60)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Passive Birth Cohort
This will be a multicenter, prospective, observational cohort study conducted across the Lyon Public hospital maternity (HFME : Hospital for women, mother and children, Croix-Rousse, Lyon-Sud) recruited from the general population.
Infants born between October 2019 and march 2020. At birth the remains (after diagnosis use) of cord blood samples will be store. Groups of RSVh cases and control will be class at one year of age using the hospital data (RSV must be confirmed by RT-PCR). Parents will be informed of the protocol. If enrolled available hospital data will be use and RSV serology testing perform on the store blood cordon.
Not applicable (no intervention)
Not applicable (no intervention)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Not applicable (no intervention)
Not applicable (no intervention)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parents living in the Rhone Alpes Auvergne region
Exclusion Criteria
* Parents living outside the region
1 Day
4 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRSVH_2019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.